Advanced glycation end-products formation cascade (AGE formation cascade)

The advanced glycation end-products (AGEs) formation cascade is a non-enzymatic biochemical pathway, primarily the Maillard reaction, where reducing sugars react with amino groups on proteins, lipids, and nucleic acids (MDPI, 2024; AHA, 2006). This process leads to the formation of irreversible cross-links that compromise the structural integrity and function of tissues, particularly affecting long-lived proteins like collagen and elastin (NIH, 2019). The accumulation of AGEs is significantly accelerated under conditions of chronic hyperglycemia, such as diabetes mellitus, and is a key contributor to the development of microvascular and macrovascular complications (ACS, 2023; ResearchGate, 2025). Beyond structural damage, AGEs act as ligands for the Receptor for Advanced Glycation End-products (RAGE), triggering pro-inflammatory and pro-oxidative signaling pathways through NF-κB activation (NIH, 2021). Therapeutic strategies targeting this cascade include inhibitors of AGE formation, such as aminoguanidine and pyridoxamine, and AGE-breaking compounds like alagebrium (NIH, 2022; MDPI, 2024). Despite their potential, many candidates have faced challenges in clinical trials due to safety concerns or insufficient efficacy in reversing established damage (NIH, 2019; ACS, 2023).

Other names

Maillard reactionGlycation cascadeNon-enzymatic browningProtein glycation pathway

Inhibition of non-enzymatic glycation by scavenging reactive carbonyl intermediates, preventing the formation of advanced glycation end-products, and breaking established protein-protein cross-links (NIH, 2022; MDPI, 2024).